Lipitor Cuts Merkley From Review

Join us at Brandweek Sept. 12–16 in Miami alongside leading CMOs, founders and change makers from GatoradeMarriottAlo YogaCampbell'sUncommon James and more. Book now.

NEW YORK Omnicom Group’s Merkley + Partners, the creative incumbent on Pfizer’s Lipitor, has been eliminated from the client’s review, leaving three New York shops vying for the estimated $60-80 million account, sources said.

The remaining shops are WPP Group’s JWT, Publicis Groupe’s The Kaplan Thaler Group and mcgarrybowen, an independent, according to sources.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in